[1,2,4]Triazolo[3,4‐b][1,3,4]Thiadiazin‐3‐Yl)methyl)pyrimidin‐4( 3H )‐One Derivatives as New Therapeutic Candidates as COX ‐ II Inhibitors: Green Synthetic Approach and In Silico Studies

Similar Items

• Green MCR‐Based Synthesis, In Vitro COX Inhibition, and Molecular Docking Studies of Novel Triazolo–Thiadiazine–Oxepine Hybrids
  by: Mehul Ramoliya, et al.
  Published: (2026)
• A Click Synthesis, Molecular Docking and Anticancer Studies of Benzo[ d ]azepine‐1,2,3‐triazole Hybrids Against Breast and Lung Cancer Cell‐Lines
  by: Kevalsinh Rathod, et al.
  Published: (2025)
• An efficient one‐pot, three‐component synthesis of novel [1,2,4]triazolo [4′,3′:1,5][1,2,4]triazolo[3,4‐b][1,3,4]thiadiazine derivatives and their molecular docking studies
  by: Parameshwara Chary Jilloju, et al.
  Published: (2024)
• Synthesis of novel pyrido[3,4‐d]pyrimidine‐thiazolidione‐1,2,4‐oxadiazoles as potent EGFR targeting anticancer agents
  by: Botla Durga Varaprasadu, et al.
  Published: (2024)
• Synthesis of novel [1,2,3]triazolo[4′,5′:3,4]pyrrolo[1,2‐a]thieno[2,3‐d] pyrimidines: Potent EGFR targeting anti‐breast cancer agents
  by: Rajkumar Samala, et al.
  Published: (2024)